Genetic Testing (PGT/PGD) in Bihar: A Complete Clinical Guide for Couples Seeking Healthy Pregnancies

Preimplantation Genetic Testing (PGT) is an umbrella term for laboratory techniques performed on embryos before they are transferred into the uterus during an IVF cycle. It is divided into three clinically distinct categories. PGT-A (formerly PGS) screens embryos for aneuploidy — abnormal chromosome numbers such as trisomies or monosomies — which are the most common cause of implantation failure and miscarriage. PGT-M (formerly PGD) tests for specific single-gene mutations, making it essential for carriers of hereditary diseases. PGT-SR identifies structural chromosomal rearrangements such as translocations that a parent may carry silently but pass to offspring.

In practical terms, a fertility embryologist performs a biopsy on a Day-5 blastocyst embryo, extracting 5–8 trophectoderm cells without harming the embryo. These cells are sent to a specialised genetics laboratory where next-generation sequencing (NGS) or array comparative genomic hybridisation (aCGH) is used to generate a complete chromosomal or genetic map. The embryologist and genetics team then identify which embryos are euploid (chromosomally normal) and free of the targeted mutation. Only these healthy embryos are selected for frozen embryo transfer, dramatically improving the probability of a live birth compared to transferring untested embryos.

PGT and PGD are not only for couples with complex medical histories — several clinical scenarios make them strongly advisable, and these scenarios are common among Bihar's patient population. Couples who have experienced two or more unexplained pregnancy losses should consider PGT-A, because in many such cases the miscarriages are driven by chromosomally abnormal embryos rather than uterine or hormonal problems. Women above 35 years of age, whose egg quality naturally declines and whose embryos carry a higher aneuploidy risk, benefit substantially from PGT-A before transfer.

PGT-M is critically important for couples who are both carriers of autosomal recessive conditions. In Bihar and across eastern India, beta-thalassaemia carrier rates are clinically significant, and if both partners carry the mutation, every pregnancy has a 25% chance of producing a child with thalassaemia major. Sickle cell anaemia, spinal muscular atrophy (SMA), and Duchenne muscular dystrophy are other conditions for which PGD testing is routinely offered. Couples in Patna, Gaya, or Bhagalpur who have already had an affected child, or where family genetic screening has revealed carrier status, should discuss PGT-M with a reproductive genetics counsellor before beginning IVF. Repeated implantation failure — defined as three or more failed good-quality embryo transfers — is another strong clinical indication.

Given Bihar's regional disease epidemiology, certain genetic conditions are of particular clinical relevance when counselling couples about PGD. Beta-thalassaemia is the most frequently requested single-gene disorder for PGT-M in eastern India. The state has a historically high prevalence of haemoglobinopathies, and the HomeIVF Medical Board recommends haemoglobin electrophoresis screening for both partners before commencing any IVF cycle where one partner is a known carrier.

Spinal muscular atrophy (SMA) caused by mutations in the SMN1 gene is another condition for which PGT-M is now routinely available. With newborn SMA treatment costs being prohibitively high in India, prevention via PGD is considered a compassionate and cost-effective strategy. Fragile X syndrome, which causes intellectual disability and is the leading inherited cause of autism spectrum disorder, can also be screened via PGT-M. Chromosomal translocations — where segments of chromosomes are rearranged — are often discovered only after multiple miscarriages or failed IVF cycles. Couples in Muzaffarpur or Darbhanga who have undergone recurrent pregnancy loss workups and been found to carry a balanced translocation are ideally served by PGT-SR, which can identify viable embryos for transfer with far greater precision than conventional IVF alone.

Understanding the clinical pathway demystifies the process and reduces anxiety for Bihar couples approaching genetic testing for the first time. The journey begins with a comprehensive genetic counselling session, where the HomeIVF Medical Board reviews personal and family medical histories, existing genetic reports, and determines which PGT category — A, M, or SR — is clinically appropriate. For PGT-M, a probe design period of 4–8 weeks is required before the IVF stimulation cycle begins, as the laboratory must engineer a customised genetic test specific to the couple's mutation.

Once the IVF stimulation cycle starts, the process mirrors standard IVF: ovarian stimulation with injectable gonadotrophins, follicle monitoring via ultrasound, egg retrieval under sedation, and fertilisation using ICSI to ensure clean embryo samples for biopsy. On Day 5 or Day 6, blastocyst-stage embryos undergo trophectoderm biopsy and are immediately vitrified (frozen). Biopsy samples are shipped to the genetics lab and results typically return within 10–21 days. A subsequent frozen embryo transfer (FET) cycle is then planned based on results. HomeIVF coordinates the entire logistics chain — from stimulation monitoring in Patna or nearby cities to embryo biopsy at affiliated accredited labs — so patients do not need to juggle multiple providers across different cities.

Before a couple can proceed to PGT, a structured diagnostic workup establishes baseline fertility parameters and confirms the genetic indication. For PGT-A, standard IVF investigations suffice: serum AMH, antral follicle count (AFC) via transvaginal ultrasound, Day-2 FSH and LH, a semen analysis with DNA fragmentation index (DFI), and a uterine cavity assessment via sonohysterogram or hysteroscopy. These tests confirm that the couple can generate sufficient blastocysts for biopsy — typically at least two to three — to make the PGT cycle clinically meaningful.

For PGT-M, the couple must first undergo carrier status confirmation through molecular genetic testing — typically a blood draw sent to a certified genetics laboratory. This is now possible through HomeIVF's home blood collection service across major districts in Bihar, including Patna, Muzaffarpur, and Gaya, removing the need to visit a metropolitan diagnostic centre. The laboratory uses the confirmed mutation data to design the single-gene probe. For PGT-SR, karyotyping of both partners — a test that analyses the full chromosomal structure — is the critical prerequisite. Results take 3–4 weeks and form the blueprint for the SR probe design. HomeIVF's care coordinators guide families through every test, explain reports in local languages where needed, and ensure no diagnostic step is skipped or misinterpreted.

HomeIVF does not replace the senior embryologists and reproductive geneticists who perform these highly technical procedures — it delivers their expertise directly to Bihar patients through a coordinated hybrid care model. Consultations are conducted via video with senior fertility specialists and genetic counsellors from HomeIVF's network, meaning a couple in Bhagalpur or Araria receives the same depth of clinical review as a patient walking into a premium clinic in Mumbai.

For procedures requiring physical presence — such as egg retrieval and embryo transfer — HomeIVF partners with accredited IVF laboratories that meet the stringent quality benchmarks set by the HomeIVF Medical Board. Stimulation monitoring, which requires serial ultrasounds and blood oestradiol measurements, is coordinated at diagnostic centres within the patient's district, minimising travel. Embryo biopsy is performed by certified embryologists at the affiliated partner lab, and the genetic sample is dispatched to an NABL-accredited or internationally certified genetics laboratory for next-generation sequencing analysis. HomeIVF's IVF packages start from ₹1.5 lakh, and the care team provides a transparent, itemised breakdown of additional PGT costs during the initial consultation so families can plan without financial surprises.

Despite its clinical importance, uptake of PGT/PGD in Bihar has been constrained by several interrelated barriers. Awareness is the first obstacle: many couples who are ideal PGT candidates — such as those with recurrent miscarriages or known carrier status — are simply not informed by their treating gynaecologist that such testing exists and is accessible in India. HomeIVF's digital outreach in Hindi and Maithili, targeted at Bihar's population, specifically aims to close this information gap.

Geography is the second barrier. Bihar lacks the dense cluster of high-complexity IVF centres found in Delhi or Bengaluru. Patients in Darbhanga, Sitamarhi, or Madhubani historically had to travel hundreds of kilometres for a single ultrasound appointment. HomeIVF's distributed monitoring model solves this by mapping partner diagnostic centres across Bihar's districts. The third barrier is cost transparency — many Bihar families hesitate because they fear hidden charges. HomeIVF's structured package model addresses this directly. A fourth barrier is stigma and psychological burden: couples carrying genetic conditions often feel guilt or fear judgment. The HomeIVF Medical Board's counselling framework includes dedicated emotional support sessions alongside clinical care, ensuring patients in Bihar receive holistic, compassionate fertility treatment rather than transactional IVF services.

Consider a couple from Patna in their mid-30s who had experienced three consecutive miscarriages over four years. Each pregnancy ended before 10 weeks with no clear uterine or hormonal cause identified. A karyotype revealed that the husband carried a balanced Robertsonian translocation — a silent chromosomal rearrangement that caused no health issues in him but resulted in unbalanced chromosomes in approximately 50% of embryos. With PGT-SR, the couple underwent IVF, and out of six blastocysts biopsied, two were confirmed as chromosomally balanced. A single frozen embryo transfer resulted in an ongoing pregnancy — their first after years of loss.

Or consider a young couple from Muzaffarpur where both partners were identified as beta-thalassaemia carriers after a routine premarital screening camp. Rather than proceeding with a natural pregnancy — which carried a 25% risk of a child with thalassaemia major — they chose IVF with PGT-M. The customised probe designed for their specific HBB gene mutation identified two unaffected embryos among four biopsied. Their healthy, unaffected daughter was born at term. These archetypes reflect real clinical outcomes seen with PGT globally and represent exactly the population HomeIVF is committed to serving across Bihar's cities and districts.